US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARS PHARMACEUTICALS INC

8.07

-0.4950-5.78%

Volume:2.11M

Turnover:17.08M

Market Cap:797.21M

PE:-4.64

High:8.64

Open:8.57

Low:7.61

Close:8.56

52wk High:18.90

52wk Low:6.66

Shares:98.85M

Float Shares:55.27M

Volume Ratio:0.93

T/O Rate:3.83%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7400

EPS(LYR):-1.7400

ROE:-92.33%

ROA:-33.04%

PB:6.98

PE(LYR):-4.64

Loading ...

Overview Company News Filings

ARS Gets FDA Approval to Remove Age Requirement for Allergic-Reaction Nasal Spray

ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement

BRIEF-Ars Pharmaceuticals Receives FDA Approval To Remove Age Requirement From Neffy® 1 Mg (Epinephrine Nasal Spray) Label

ARS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

BRIEF-ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

ARS Pharmaceuticals Reports Q4 Net Loss

MT Newswires Live

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss

MT Newswires Live

ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales

ARS Pharmaceuticals FY2025 net product revenue rose 895% to USD 72.19 million as net loss widened to USD 171.3 million

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on Neffy® (Epinephrine Nasal Spray) Commercialization

THOMSON REUTERS

ARS Pharmaceuticals Inc: Neffy Delivers $72.2 Mln of U.S. Net Product Revenue in First Full Year

THOMSON REUTERS

ARS Pharmaceuticals Inc - ARS Pharma to Expand Sales Force From 106 to 150 Beginning Q2 2026

THOMSON REUTERS

ARS Pharmaceuticals Inc - Regulatory Approval for Neffy in Canada Expected Q2 2026, Launch Expected Later in 2026

THOMSON REUTERS

ARS Pharmaceuticals Q4 Revenue USD 28.1 Million VS. Ibes Estimate USD 25.6 Million

THOMSON REUTERS

Press Release: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy(R) (epinephrine nasal spray) Commercialization

U.S. Earnings Preview: Before Market Open March 9

ARS Pharmaceuticals Inc. published an update to their financial calendar

ALK posts Q4 EBIT of DKK 387 million up 88%

ARS Pharmaceuticals Unveils New Clinical Data Highlighting neffy Nasal Epinephrine Advantages

EU Panel Recommends Approval of ARS Pharma’s EURneffy 1 mg Nasal Adrenaline Spray for Children

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SPRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":8.065,"timestamp":1774641512039,"preClose":8.56,"halted":0,"volume":2114141,"delay":0,"changeRate":-0.05782710280373843,"floatShares":55270496,"shares":98848611,"eps":-1.74,"marketStatus":"Trading","change":-0.495,"latestTime":"03-27 15:58:32 EDT","open":8.57,"high":8.64,"low":7.61,"amount":17083599.645394,"amplitude":0.120327,"askPrice":8.07,"askSize":2704,"bidPrice":8.06,"bidSize":5165,"shortable":0,"etf":0,"ttmEps":-1.74,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":8.56,"preHourTrading":{"tag":"盘前","latestPrice":8.5,"preClose":8.56,"latestTime":"09:29 EDT","volume":19256,"amount":164915.585744,"timestamp":1774618199905,"change":-0.06,"changeRate":-0.007009,"amplitude":0.047897},"postHourTrading":{"tag":"盘后","latestPrice":8.56,"preClose":8.56,"latestTime":"19:48 EDT","volume":51457,"amount":440470.17,"timestamp":1774568907683,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.93364,"impliedVol":0.9895,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":55270496,"roa":"-33.04%","roe":"-92.33%","lyrEps":-1.74,"volumeRatio":0.933651,"shares":98848611,"dividePrice":0,"high":8.64,"amplitude":0.120327,"preClose":8.56,"low":7.61,"week52Low":6.66,"pbRate":"6.98","psRate":"9.46","week52High":18.9,"institutionHeld":0,"latestPrice":8.065,"committee":0.312746,"eps":-1.74,"divideRate":0,"volume":2114166,"delay":0,"ttmEps":-1.74,"open":8.57,"prevYearClose":11.65,"prevWeekClose":8.17,"prevMonthClose":9.28,"prevQuarterClose":11.65,"fiveDayClose":8.17,"twentyDayClose":9.28,"sixtyDayClose":11.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-09","symbol":"SPRY","fiscalQuarterEnding":"2025/12","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773028800000,"reportTimeType":"pre","actualEps":-0.42},{"market":"US","date":"2025-11-10","symbol":"SPRY","fiscalQuarterEnding":"2025/09","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2025-08-13","symbol":"SPRY","fiscalQuarterEnding":"2025/06","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2025-05-14","symbol":"SPRY","fiscalQuarterEnding":"2025/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1762315200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2026-03-26","current":-4.91954,"percent":0.9508,"low":-115.157754,"twenty":-29.548145,"median":-17.734844,"eighty":-11.440949,"high":184.020638,"avg":-16.687887,"sd":46.966383,"marketCap":784448725},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.313866,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":860429873},{"date":"2024-06-07","current":-17.177383,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":853647205},{"date":"2024-06-14","current":-16.884919,"twenty":-27.543213,"median":-15.872834,"eighty":-9.957071,"marketCap":839112916},{"date":"2024-06-21","current":-15.929536,"twenty":-27.026227,"median":-15.872834,"eighty":-9.981995,"marketCap":791634241},{"date":"2024-06-28","current":-16.592455,"twenty":-26.233342,"median":-15.857321,"eighty":-10.038073,"marketCap":824578628},{"date":"2024-07-05","current":-17.742813,"twenty":-26.122559,"median":-15.901185,"eighty":-10.097267,"marketCap":881746829},{"date":"2024-07-12","current":-22.129772,"twenty":-26.004391,"median":-15.977907,"eighty":-10.112844,"marketCap":1099761155},{"date":"2024-07-19","current":-20.550467,"twenty":-25.84191,"median":-16.008119,"eighty":-10.131537,"marketCap":1021275998},{"date":"2024-07-26","current":-21.408361,"twenty":-25.598187,"median":-16.06602,"eighty":-10.234348,"marketCap":1063909910},{"date":"2024-08-02","current":-19.302621,"twenty":-25.251068,"median":-16.155521,"eighty":-10.620668,"marketCap":959263034},{"date":"2024-08-09","current":-23.520911,"twenty":-24.881793,"median":-16.206368,"eighty":-10.941562,"marketCap":1054724705},{"date":"2024-08-16","current":-28.81744,"twenty":-25.84191,"median":-16.286222,"eighty":-11.035026,"marketCap":1292231647},{"date":"2024-08-23","current":-28.017556,"twenty":-27.270827,"median":-16.393243,"eighty":-11.081758,"marketCap":1256363252},{"date":"2024-08-30","current":-28.060793,"twenty":-27.941591,"median":-16.401625,"eighty":-11.197031,"marketCap":1258302084},{"date":"2024-09-06","current":-24.558599,"twenty":-27.79336,"median":-16.442915,"eighty":-11.309188,"marketCap":1101256678},{"date":"2024-09-13","current":-28.752585,"twenty":-27.79336,"median":-16.472628,"eighty":-11.620736,"marketCap":1289323399},{"date":"2024-09-20","current":-31.930502,"twenty":-27.995938,"median":-16.576918,"eighty":-11.620736,"marketCap":1431827564},{"date":"2024-09-27","current":-30.95767,"twenty":-28.060793,"median":-16.631178,"eighty":-11.714201,"marketCap":1388203840},{"date":"2024-10-04","current":-30.67663,"twenty":-28.212122,"median":-16.751589,"eighty":-11.833393,"marketCap":1375601431},{"date":"2024-10-11","current":-31.39004,"twenty":-28.39555,"median":-16.860498,"eighty":-11.83882,"marketCap":1407592162},{"date":"2024-10-18","current":-34.567957,"twenty":-28.752585,"median":-16.884919,"eighty":-11.967761,"marketCap":1550096327},{"date":"2024-10-25","current":-31.930502,"twenty":-28.968769,"median":-17.021402,"eighty":-12.05734,"marketCap":1431827564},{"date":"2024-11-01","current":-32.989808,"twenty":-29.172776,"median":-17.10772,"eighty":-12.236498,"marketCap":1479328953},{"date":"2024-11-08","current":-36.837898,"twenty":-29.53085,"median":-17.177383,"eighty":-12.27233,"marketCap":1651885017},{"date":"2024-11-15","current":-27.728261,"twenty":-29.574087,"median":-17.203935,"eighty":-12.290246,"marketCap":1361568504},{"date":"2024-11-22","current":-27.708469,"twenty":-29.53085,"median":-17.216378,"eighty":-12.329028,"marketCap":1360596650},{"date":"2024-11-29","current":-28.717849,"twenty":-29.510269,"median":-17.294264,"eighty":-12.329028,"marketCap":1410161242},{"date":"2024-12-06","current":-27.748052,"twenty":-29.318167,"median":-17.323614,"eighty":-12.355333,"marketCap":1362540359},{"date":"2024-12-13","current":-23.552198,"twenty":-29.200708,"median":-17.377363,"eighty":-12.390575,"marketCap":1156507152},{"date":"2024-12-20","current":-22.127191,"twenty":-29.174826,"median":-17.429503,"eighty":-12.426406,"marketCap":1086533610},{"date":"2024-12-27","current":-21.355313,"twenty":-29.123341,"median":-17.460097,"eighty":-12.465821,"marketCap":1048631275},{"date":"2025-01-03","current":-22.146983,"twenty":-29.064257,"median":-17.508842,"eighty":-12.501652,"marketCap":1087505465},{"date":"2025-01-10","current":-22.245942,"twenty":-29.025066,"median":-17.556082,"eighty":-12.530317,"marketCap":1092364739},{"date":"2025-01-17","current":-24.878247,"twenty":-29.013807,"median":-17.625827,"eighty":-12.566149,"marketCap":1221621420},{"date":"2025-01-24","current":-27.866803,"twenty":-28.968769,"median":-17.665522,"eighty":-12.594815,"marketCap":1368371488},{"date":"2025-01-31","current":-25.768876,"twenty":-28.968769,"median":-17.692748,"eighty":-12.61273,"marketCap":1265354884},{"date":"2025-02-07","current":-23.591782,"twenty":-28.81744,"median":-17.719962,"eighty":-12.684394,"marketCap":1158450862},{"date":"2025-02-14","current":-23.7897,"twenty":-28.81245,"median":-17.725862,"eighty":-12.70231,"marketCap":1168169409},{"date":"2025-02-21","current":-22.245942,"twenty":-28.80529,"median":-17.742813,"eighty":-12.730975,"marketCap":1092364739},{"date":"2025-02-28","current":-20.741768,"twenty":-28.766646,"median":-17.750677,"eighty":-12.878556,"marketCap":1018503778},{"date":"2025-03-07","current":-21.474063,"twenty":-28.753554,"median":-17.783612,"eighty":-12.988431,"marketCap":1054462403},{"date":"2025-03-14","current":-23.492823,"twenty":-28.724796,"median":-17.918291,"eighty":-13.032048,"marketCap":1153591588},{"date":"2025-03-21","current":151.633005,"twenty":-28.645299,"median":-17.929848,"eighty":-12.988431,"marketCap":1212760777},{"date":"2025-03-28","current":153.227851,"twenty":-28.604711,"median":-17.78435,"eighty":-12.670061,"marketCap":1225516351},{"date":"2025-04-04","current":157.030944,"twenty":-28.551598,"median":-17.756493,"eighty":-12.515985,"marketCap":1255933491},{"date":"2025-04-11","current":172.365997,"twenty":-28.537065,"median":-17.742813,"eighty":-12.355333,"marketCap":1378583246},{"date":"2025-04-17","current":182.548472,"twenty":-28.53527,"median":-17.728408,"eighty":-12.28308,"marketCap":1460022683},{"date":"2025-04-25","current":168.930945,"twenty":-28.478265,"median":-17.719962,"eighty":-11.916185,"marketCap":1351109701},{"date":"2025-05-02","current":177.55989,"twenty":-28.413636,"median":-17.701176,"eighty":-11.620736,"marketCap":1420124003},{"date":"2025-05-09","current":165.034919,"twenty":-28.363303,"median":-17.672598,"eighty":-11.047488,"marketCap":1319949281},{"date":"2025-05-16","current":-85.348526,"twenty":-28.478265,"median":-17.679674,"eighty":-10.985179,"marketCap":1335704429},{"date":"2025-05-23","current":-91.122103,"twenty":-28.610323,"median":-17.701176,"eighty":-11.047488,"marketCap":1426060905},{"date":"2025-05-30","current":-97.209461,"twenty":-28.755493,"median":-17.719962,"eighty":-11.103567,"marketCap":1521328059},{"date":"2025-06-06","current":-84.344425,"twenty":-28.908237,"median":-17.728408,"eighty":-11.22507,"marketCap":1319990259},{"date":"2025-06-13","current":-90.369027,"twenty":-29.139819,"median":-17.742813,"eighty":-11.433807,"marketCap":1414275278},{"date":"2025-06-20","current":-99.845224,"twenty":-29.414401,"median":-17.756493,"eighty":-11.620736,"marketCap":1562577755},{"date":"2025-06-27","current":-113.463334,"twenty":-29.625971,"median":-17.78435,"eighty":-11.639429,"marketCap":1775701182},{"date":"2025-07-03","current":-103.673356,"twenty":-29.970507,"median":-17.918291,"eighty":-11.714201,"marketCap":1622488027},{"date":"2025-07-11","current":-112.835772,"twenty":-30.109473,"median":-17.96922,"eighty":-11.833393,"marketCap":1765879826},{"date":"2025-07-18","current":-115.157754,"twenty":-30.373971,"median":-18.060207,"eighty":-11.83882,"marketCap":1802218844},{"date":"2025-07-25","current":-112.459234,"twenty":-30.612951,"median":-18.156476,"eighty":-11.967761,"marketCap":1759987013},{"date":"2025-08-01","current":-110.953084,"twenty":-30.649879,"median":-18.318793,"eighty":-12.05734,"marketCap":1736415758},{"date":"2025-08-08","current":-110.764815,"twenty":-30.849578,"median":-18.491503,"eighty":-12.236498,"marketCap":1733469351},{"date":"2025-08-15","current":-29.781475,"twenty":-31.056082,"median":-18.779127,"eighty":-12.27233,"marketCap":1430017096},{"date":"2025-09-05","current":-22.001657,"twenty":-31.011769,"median":-19.029654,"eighty":-12.286663,"marketCap":1056453542},{"date":"2025-09-12","current":-20.890254,"twenty":-30.966274,"median":-19.71207,"eighty":-12.321272,"marketCap":1003087320},{"date":"2025-09-19","current":-20.43746,"twenty":-30.871196,"median":-20.12152,"eighty":-12.329028,"marketCap":981345526},{"date":"2025-09-26","current":-19.63478,"twenty":-30.797693,"median":-20.134768,"eighty":-12.355333,"marketCap":942803254},{"date":"2025-10-03","current":-21.157814,"twenty":-30.698248,"median":-20.149319,"eighty":-12.390575,"marketCap":1015934744},{"date":"2025-10-10","current":-23.833413,"twenty":-30.67,"median":-20.178749,"eighty":-12.426406,"marketCap":1144408982},{"date":"2025-10-17","current":-20.807928,"twenty":-30.653572,"median":-20.2775,"eighty":-12.47657,"marketCap":999134267},{"date":"2025-10-24","current":-19.861177,"twenty":-30.649879,"median":-20.299599,"eighty":-12.515985,"marketCap":953674152},{"date":"2025-10-31","current":-17.74128,"twenty":-30.620337,"median":-20.187599,"eighty":-12.551817,"marketCap":851883024},{"date":"2025-11-07","current":-16.866565,"twenty":-30.612951,"median":-20.149319,"eighty":-12.587649,"marketCap":809881831},{"date":"2025-11-14","current":-10.386267,"twenty":-30.612951,"median":-20.12152,"eighty":-12.426406,"marketCap":831316818},{"date":"2025-11-21","current":-8.311484,"twenty":-30.553867,"median":-19.933213,"eighty":-12.321272,"marketCap":665251152},{"date":"2025-11-28","current":-11.781806,"twenty":-30.491905,"median":-19.75827,"eighty":-12.164835,"marketCap":943015748},{"date":"2025-12-05","current":-12.312852,"twenty":-30.408561,"median":-19.63478,"eighty":-11.836649,"marketCap":985520651},{"date":"2025-12-12","current":-13.856589,"twenty":-30.373971,"median":-19.314339,"eighty":-11.916185,"marketCap":1109081415},{"date":"2025-12-19","current":-12.127603,"twenty":-30.309116,"median":-19.029654,"eighty":-12.021508,"marketCap":970693360},{"date":"2025-12-26","current":-14.177687,"twenty":-30.256997,"median":-18.779127,"eighty":-12.085445,"marketCap":1134782054},{"date":"2026-01-02","current":-14.387635,"twenty":-30.230821,"median":-18.672648,"eighty":-12.149382,"marketCap":1151586318},{"date":"2026-01-09","current":-13.523142,"twenty":-30.165419,"median":-18.491503,"eighty":-12.241889,"marketCap":1082392290},{"date":"2026-01-16","current":-13.696041,"twenty":-30.101841,"median":-18.441052,"eighty":-12.263452,"marketCap":1096231095},{"date":"2026-01-23","current":-13.053846,"twenty":-30.071312,"median":-18.318793,"eighty":-12.263452,"marketCap":1044829818},{"date":"2026-01-30","current":-12.621599,"twenty":-30.016829,"median":-18.156476,"eighty":-12.27233,"marketCap":1010232804},{"date":"2026-02-06","current":-11.942355,"twenty":-30.006457,"median":-18.060207,"eighty":-12.27233,"marketCap":955866068},{"date":"2026-02-13","current":-10.880263,"twenty":-29.970507,"median":-17.96922,"eighty":-12.251102,"marketCap":870856262},{"date":"2026-02-20","current":-11.658307,"twenty":-29.864079,"median":-17.933958,"eighty":-12.08391,"marketCap":933130887},{"date":"2026-02-27","current":-11.534808,"twenty":-29.792674,"median":-17.810106,"eighty":-11.837735,"marketCap":923246026},{"date":"2026-03-06","current":-11.26311,"twenty":-29.719333,"median":-17.772592,"eighty":-11.771926,"marketCap":901499332},{"date":"2026-03-13","current":-4.776529,"twenty":-29.651913,"median":-17.742813,"eighty":-11.650793,"marketCap":818209809},{"date":"2026-03-20","current":-4.782325,"twenty":-29.587058,"median":-17.742047,"eighty":-11.574328,"marketCap":819202782},{"date":"2026-03-26","current":-4.579439,"twenty":-29.548145,"median":-17.734844,"eighty":-11.440949,"marketCap":784448725}],"updateTime":1774610319621},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622294128","title":"ARS Gets FDA Approval to Remove Age Requirement for Allergic-Reaction Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2622294128","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622294128?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:27","pubTimestamp":1774614420,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals received approval from the Food and Drug Administration to remove the age requirement for its neffy nasal spray to treat allergic reactions.Children were previously required to be at least four years old to receive the 1 milligram dose of the spray.All children and adults who weigh at least 33 pounds will now be able to use it.\"Caregivers often face tremendous fear administering needle-based treatment options but now, neffy can be used safely in our most vulnerable young patients,\" said Chief Executive Richard Lowenthal.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4139","BK4585","SPRY"],"gpt_icon":0},{"id":"2622291518","title":"ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622291518","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622291518?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:16","pubTimestamp":1774613784,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) announced that the FDA has approved updating the neffy 1 mg prescribing information to remove the age criteria so all ch...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-receives-fda-approval-to-remove-neffy-1-mg-age-requirement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-receives-fda-approval-to-remove-neffy-1-mg-age-requirement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4588","LABU","BK4139","BK4585"],"gpt_icon":0},{"id":"2622826037","title":"BRIEF-Ars Pharmaceuticals Receives FDA Approval To Remove Age Requirement From Neffy® 1 Mg (Epinephrine Nasal Spray) Label","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826037","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826037?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:07","pubTimestamp":1774613231,"startTime":"0","endTime":"0","summary":"BRIEF-Ars Pharmaceuticals Receives FDA Approval To Remove Age Requirement From Neffy 1 Mg (Epinephrine Nasal Spray) LabelARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS RECEIVES FDA APPROVAL TO REM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUA11RQ7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618621668","title":"ARS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621668?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:31","pubTimestamp":1773063076,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL8N3ZX1BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618640761","title":"BRIEF-ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640761","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640761?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054308,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results March 9 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS Q4 EPS USD -0.42ARS PHARMACEUTICALS Q4 NET ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLXB50D2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618771642","title":"ARS Pharmaceuticals Reports Q4 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618771642","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618771642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:18","pubTimestamp":1773051523,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) reported a Q4 net loss Monday of $0.42 per diluted share.Three analysts surveyed by FactSet expected a loss of $0.39.Revenue for the quarter ended Dec. 31 was $28.1 million.Analysts surveyed by FactSet expected revenue of $25.6 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618764222","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618764222","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618764222?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:16","pubTimestamp":1773051379,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618642108","title":"ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642108","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642108?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:10","pubTimestamp":1773051002,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy salesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectationsCompany reported Q4 net loss of $41.3 mlnCompany holds $245 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX0CN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","LU0154245756.USD","BK4588","BK4533","BK4139","LU0203347892.USD","LU0154245673.USD","LU0203345920.USD","SPRY","CMI","BK4585","BK4149"],"gpt_icon":0},{"id":"2618642540","title":"ARS Pharmaceuticals FY2025 net product revenue rose 895% to USD 72.19 million as net loss widened to USD 171.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642540?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050452,"startTime":"0","endTime":"0","summary":"ARS Pharma reported Q4 2025 total revenue of USD 28.1 million, including USD 20.3 million in U.S. net product revenue from neffy. Q4 2025 net loss was USD 41.3 million, or USD 0.42 per share . For FY 2025, total revenue was USD 84.28 million, including USD 72.2 million in U.S. net product revenue from neffy. FY 2025 net loss was USD 171.3 million, or USD 1.74 per share . ARS Pharma ended 2025 with USD 245 million in cash, cash equivalents and short-term investments, and said it plans to expand its sales force to 150 from 106 starting in Q2 2026 while keeping 2026 SG&A spending at a similar annualized level.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5wQ12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","BK4112","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","BK4139","SG9999014039.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2618864255","title":"ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on Neffy® (Epinephrine Nasal Spray) Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2618864255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618864255?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA4PS3LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2618642584","title":"ARS Pharmaceuticals Inc: Neffy Delivers $72.2 Mln of U.S. Net Product Revenue in First Full Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642584?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA4PS3LV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618642546","title":"ARS Pharmaceuticals Inc - ARS Pharma to Expand Sales Force From 106 to 150 Beginning Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642546?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLXB50D2B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2618642511","title":"ARS Pharmaceuticals Inc - Regulatory Approval for Neffy in Canada Expected Q2 2026, Launch Expected Later in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642511?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLXB50D2B:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2618464255","title":"ARS Pharmaceuticals Q4 Revenue USD 28.1 Million VS. Ibes Estimate USD 25.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618464255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618464255?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLXB50D2B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2618528642","title":"Press Release: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy(R) (epinephrine nasal spray) Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2618528642","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618528642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050400,"startTime":"0","endTime":"0","summary":"neffy delivers $72.2 million of U.S. net product revenue in first full year. Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026. Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even. \"2025 was an important year for ARS Pharma as we established neffy as a differentiated, scalable epinephrine treatment of choice. We have built a strong base business with initial prescriptions expected to begin renewing in 2026 as product reaches expiration. This shift towards renewals, combined with continued growth in new neffy patients, positions us to accelerate market share expansion,\" said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma.and $0.9 million in supply revenue from partners. The cash value of. and $0.1 million was recorded to the financing liability on the company's. collaboration revenue, and $2.4 million from supply agreements. The cash","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4588","EMA","CHMP","BK4232","BK4022","BK4008","BK4585","BK4081","ALK","BK4139","BK4500","R","SPRY"],"gpt_icon":0},{"id":"2618644840","title":"U.S. Earnings Preview: Before Market Open March 9","url":"https://stock-news.laohu8.com/highlight/detail?id=2618644840","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618644840?lang=en_us&edition=fundamental","pubTime":"2026-03-09 17:30","pubTimestamp":1773048600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results before the market opens.Korn Ferry's third-quarter EPS is forecast at $1.23, compared with $1.10 in the prior-year period. Adjusted EPS is forecast at $1.24.Global Business Travel Group Inc.'s fourth-quarter EPS is forecast at 5 cents, compared with 16 cents in the prior-year period. Adjusted EPS is forecast at 9 cents.ARS Pharmaceuticals Inc.'s fourth-quarter EPS is forecast at a loss of 39 cents, compared with net income of 51 cents per share in the prior-year period. Adjusted EPS is forecast at a loss of 43 cents.Heritage Insurance Holdings Inc.'s fourth-quarter EPS is forecast at $1.61, compared with 66 cents in the prior-year period. Adjusted EPS is forecast at $1.74.Annexon Inc.'s fourth-quarter EPS is forecast at a loss of 32 cents, compared with a loss of 33 cents in the prior-year period.3D Syst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4539","HRTG","BK4142","GBTG","BK4505","BK4107","ANNX","DSGN","BK4139"],"gpt_icon":0},{"id":"2613784754","title":"ARS Pharmaceuticals Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613784754?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851616,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals will host a conference call and webcast on March 9, 2026  to discuss its fourth quarter and full year 2025 financial results and business highlights; dial-in information is available by registering for the event. ARS Pharma management will participate in the 10th Annual Oppenheimer Emerging Growth Conference on February 25, 2026. ARS Pharma management will participate in the Leerink Conference on March 11, 2026, with a live webcast available here. ARS Pharma management will participate in the 38th Annual ROTH Conference on March 22, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL3JXfLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","SG9999014005.SGD","SPRY","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2612996251","title":"ALK posts Q4 EBIT of DKK 387 million up 88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612996251","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612996251?lang=en_us&edition=fundamental","pubTime":"2026-02-20 14:18","pubTimestamp":1771568301,"startTime":"0","endTime":"0","summary":"ALK reported FY 2025 revenue of DKK 6,312.00 million  and EBIT of DKK 1,654.00 million , with an EBIT margin of 26%. Free cash flow was DKK 1,432.00 million, supported by higher earnings and an upfront payment from a new Chinese partnership with GenSci. For Q4 2025, revenue was DKK 1,733.00 million  and EBIT was DKK 387.00 million , with a 22% EBIT margin. By product line in FY 2025, tablet sales were DKK 3,335.00 million , SCIT/SLIT drops were DKK 2,145.00 million (+5%), and anaphylaxis and other products were DKK 832.00 million , driven by Jext and neffy. ALK highlighted strong uptake of paediatric launches of ACARIZAX and ITULAZAX, continued roll-out of neffy in Germany and the UK, and progress with partnerships including ARS Pharma, GenSci and Shionogi . The company said its phase 2 peanut SLIT tablet trial remains on track to report topline results in Q2 2026. ALK’s board recommended FY 2025 dividends of DKK 355.00 million, or DKK 1.60 per share, targeting distribution of about 30","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5MfKx9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","BK4112","BK4139","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014039.USD","SPRY","LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD"],"gpt_icon":0},{"id":"2610628315","title":"ARS Pharmaceuticals Unveils New Clinical Data Highlighting neffy Nasal Epinephrine Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=2610628315","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610628315?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728419,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. announced that five poster presentations highlighting new clinical data on neffy  will be showcased at the 2026 American Academy of Allergy, Asthma and Immunology  Annual Scientific Meeting. The presentations will include information on the clinical advancement, real-world usability, and advantages of needle-free epinephrine delivery. The company noted that neffy offers a longer shelf life compared to epinephrine auto-injectors, resulting in a more affordable, value-based price. The results of these studies, including pharmacoeconomic data and patient preference, will be presented at the upcoming meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL6Fj37s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","BK4112","BK4139","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014039.USD","SPRY","LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD"],"gpt_icon":0},{"id":"2608876861","title":"EU Panel Recommends Approval of ARS Pharma’s EURneffy 1 mg Nasal Adrenaline Spray for Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876861","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608876861?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:01","pubTimestamp":1770037281,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the expansion of the marketing authorization for EURneffy to include a 1 mg nasal adrenaline spray. This product is intended for the emergency treatment of allergic reactions, including anaphylaxis, in children weighing between 15 kg and less than 30 kg. Following expected authorization by the European Commission, EURneffy 1 mg will be marketed and distributed in the European Union by ARS Pharma's partner, ALK-Abelló A/S.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNews","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6nv9H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014013.SGD","BK4588","SPRY","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}